Viking previously reported positive results from a 28-day Phase 1 multiple ascending dose (MAD) clinical trial of the tablet formulation of VK2735 in healthy volunteers with a BMI ≥30.

The Food and Drug Administration (FDA) has approved a tablet formulation of Evrysdi ® (risdiplam) for the treatment of spinal muscular atrophy (SMA). Previously, the treatment had only been ...

KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema October 31, 2022 06:45 AM Eastern Daylight Time ...

BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA ®. BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA ... The global BRUKINSA clinical development program includes about 7,100 patients enrolled in 30 countries and regions across more than ...

Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity Wednesday, January 8, 2025 Obesity News Advertisement ...